Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells

GENBAO SHAO1*, XIAOLEI WAN1-3*, WENSHENG LAI1,3, CHAOYANG WU2, JIE JIN1, XIUWEN LIU1, YE WEI1, QIONG LIN1, LIUPING ZHANG1 and QIXIANG SHAO1

1Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013; 2Department of Oncology, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu 212002; 3Department of Oncology, The Affiliated Jurong Hospital, Jiangsu University, Zhenjiang, Jiangsu 212400, P.R. China

Received March 31, 2017; Accepted January 31, 2018

DOI: 10.3892/ol.2018.8511

Abstract. Lysine-specific demethylase 1 (LSD1) functions as a transcriptional coregulator by modulating histone methylation and has been associated with numerous high-risk cancers. Previously, our group and others identified LSD1 as an upregulated gene in ovarian cancer, and reported that the upregulation of LSD1 was associated with poor prognosis of patients with ovarian cancer. However, the role of LSD1 in ovarian cancer requires further investigation. The present study revealed that the overexpression of LSD1 significantly promoted the proliferation of SKOV3 ovarian cancer cells, while knockdown of LSD1 markedly inhibited cell proliferation and potentiated cisplatin-induced cell apoptosis, supporting LSD1 as an oncogenic protein in ovarian cancer. Mechanistic studies have indicated that LSD1 modulates the expression of cyclin dependent kinase inhibitor 1, Survivin, B-cell lymphoma-2 (Bcl-2) and Bel-2-associated X genes, which are known regulators of cell proliferation. Furthermore, LSD1 knockdown plus cisplatin synergistically impaired cell migration via the induction of the epithelial marker E-cadherin and inhibition of the mesenchymal markers, snail family transcriptional repressor 1 and Vimentin. These data of the present study indicated LSD1 as a potential regulator of ovarian cancer cell progression and suggested an unfavorable role of LSD1 in cisplatin-based regimens.

Introduction

Ovarian cancer is the leading cause of mortality in women with gynecological malignancies (1). The standard treatment of this disease comprises surgery followed by chemotherapy; however, the prognosis is limited (2). Numerous molecular targeting therapies such as poly(adenosine 5’-diphosphate-ribose) polymerase inhibitors have been applied in the treatment of advanced cases, but the observed effects have not been satisfactory (3-5). These findings suggest that there may additional molecular targets for ovarian cancer therapy.

One of these targets may be the oncogenic protein lysine-specific demethylase 1 (LSD1). LSD1 was initially reported to specifically remove mono- and dimethyl groups from methylated histone H3 at lysine 4 to suppress gene expression (6,7). LSD1 is frequently overexpressed in numerous cancer types, including breast (8), prostate (9), lung (10), neuroblastoma (11) and colon cancer (12). Importantly, the overexpression of LSD1 promotes cell invasion and migration in gastric cancer (13). It also contributes to the oncogenic potential of mixed lineage leukemia-AF9 leukemia stem cells and acute myeloid leukemia (14,15). We and others have reported that LSD1 is upregulated in ovarian cancer tissues and cell lines (16-18); however, the role of LSD1 in ovarian cancer requires further investigation.

In the present study, the function of LSD1 on SKOV3 ovarian cancer cell proliferation and its role in therapeutic response to cisplatin were investigated. The results revealed that LSD1 promoted the proliferation and migration capacity of SKOV3 cells and enhanced their resistance to cisplatin, suggesting an unfavorable role of LSD1 in cisplatin-based regimens.

Materials and methods

Cell lines and cell culture. Human ovarian epithelial cancer cell line SKOV3 was a gift from Dr. Qixiang Shao (Jiangsu University, Zhenjiang, China). The cells were cultured as described previously (18). 293T cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal...
bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at a temperature of 37°C under 5% CO₂.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from the LSD1-knockdown SKOV3 cells using TRizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions, followed by treatment with DNase I (Takara Bio, Inc., Otsu, Japan). A total of 2 µg RNA was reverse-transcribed using the PrimeScript RT Reagent Kit (Takara Bio, Inc.), according to the manufacturer's instructions (19). All gene transcripts were quantified via RT‑qPCR using a Bio‑Rad CFX96 system (Bio‑Rad, Hercules, CA, USA) with SsoFast EvaGreen Supermix (Bio‑Rad Laboratories, Inc., Hercules, CA, USA), according to the manufacturer's instructions. The primer sequences for each gene were as follows: Cyclin D1 forward, 5'-CAGTGCAGGCTCTGACCTG-3'; reverse, 5'-CTTCGATGCTGCTGGAGG-3'; cyclin-dependent kinase 2 (CDK2) forward, 5'-CGAGAGATCCTCTGCTTAAG-3'; reverse, 5'-GAATCATGAATTTCTTTGTAGA-3'; CDK inhibitor 1 (p21) forward, 5'-TGATTAACCGGGAACAG-3'; reverse, 5'-AAACAGTCTCCGGCAATG-3'; and GAPDH forward, 5'-GCAAATCTCATGGCAAGTTCG-3'; reverse, 5'-TGGCCCCCACCTTGATTTTGG-3'. The reaction parameters were as follows: an initial step at 95°C for 1 min, followed by 40 cycles at 94°C for 10 sec, 56~59°C for 20 sec, and 72°C for 20 sec. Following each PCR run, melting-curve analysis was performed for each sample to verify that a single specific product was generated. Amplicon size was confirmed by ethidium bromide staining and 2% agarose gel electrophoresis. Negative controls, composed of the PCR mix without nucleic acid, were also run with each group of samples. The abundance of each single gene was determined relative to housekeeping gene, GAPDH. Expression levels were quantified using the comparative cycle threshold 2^ΔΔCq method (20).

Western blot analysis. Total cellular proteins were isolated from the LSD1-knockdown or LSD1-overexpressing SKOV3 cells in 100 mm Petri dishes following a wash with ice-cold PBS and the addition of 200 µl Cell and Tissue Protein Extraction Reagent (Kangchen Biotech, Shanghai, China). The protein concentration was determined using the BCA Protein Assay (Kangchen Biotech). A total of 40 µg protein was separated on 8~10% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes (Bio‑Rad Laboratories, Inc.). The membranes were blocked with 5% milk/TBS-T (0.1% Tween-20) for 1 h and immunoprobed with an antibody (diluted in 5% BSA/TBS-T) against LSD1 (1:1,000; cat. no. BS1511; Bioworld Technology, Shanghai, China), Survivin (1:1,000; cat. no. BS8456; Bioworld Technology), snail family transcriptional repressor 1 (Snail; 1:500; cat. no. 9782T; Cell Signaling), Vimentin (1:500; cat. no. 9782T; Cell Signaling), E-cadherin (1:500; cat. no. 9782T; Cell Signaling), or α-tubulin (1:1,000; cat. no. BS1699; Bioworld Technology), overnight at 4°C. Immunodetection was achieved following incubation with a horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibody (1:10,000; BS13278 and BS12478, Bioworld Technology) in TBS-T for 1 h at RT. ECL reagents (Millipore, Billerica, MA, USA) were used to reveal the positive bands on the membrane (21). Images were collected with a ChemiDoc XRS system (Bio-Rad Laboratories, Inc.) and densitometry analysis was performed with an image analysis program Quantity One software v.4.6.3 (Bio-Rad Laboratories, Inc.).

Generation of stable cell lines. Lentiviruses expressing pLKO (empty vector) or pLKO-LSD1-shRNA oligos were produced as described previously (18). Shed virus was harvested at 48 and 72 h post-transduction. Infection of pLKO or pLKO-LSD1-shRNA lentivirus was performed by adding 1 ml lentiviral supernatant to SKOV3 cells at ~80% confluency in a 60 mm culture dish with 4 ml of McCoy’s 5A medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 8 µg/ml Polybrene (Sigma-Aldrich; Merck KGaA). Stable knockdown clones were obtained under 1.5 µg/ml puromycin selection for 1 week.

To generate a rtT-repressor expressing (rtTA) cell line, 293T cells were transfected with 2 µg pLVX-Tet-On (empty vector), 1.5 µg pHPR-CMV-8.2AVPR and 0.5 µg of pHPR-CMV-VSVG (lentiviral packaging plasmids) (all kind gifts from Professor Changdeng Hu; Purdue University, West Lafayette, IN, USA) using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.). After 24 h transfection, the viral supernatant was harvested and used to infect SKOV3 cells. SKOV3 cells were then selected with 200 µg/ml G418 (Sigma-Aldrich; Merck KGaA) for 1 week. The cells that survived had been stably transfected with rtTA. The rtTA cells were infected with the lentiviral particles packaged with pLVX-Tight-Puro (control vector, obtained from Professor Changdeng Hu; Purdue University, West Lafayette, IN, USA) or pLVX-tight-puro-LSD1 produced as described previously (22). The rtTA cells were selected with 2.0 µg/ml puromycin for 3 days, and then maintained in the presence of 1.0 µg/ml puromycin for one week (22). The surviving cells were considered stable clones. The stable knockdown or overexpression clones were confirmed via western blot analysis as aforementioned.

Cell proliferation assay. Cell proliferation was assessed using Cell Counting Kit (CCK)-8 and 5-ethyl-2′-deoxyuridine (EdU) incorporation assays. In the CCK-8 assay, the stable SKOV3 cell lines (5,000 cells/well) were plated in 96-well plates in 100 µl McCoy’s 5A medium per well. The cells were cultured overnight at 37°C and then treated with 1, 10 and 100 ng/ml doxycycline (Dox; Sigma-Aldrich; Merck KGaA) to induce LSD1 knockdown or overexpression for 24, 48 and 72 h at 37°C. A total of 1/10 volume of CCK-8 was then added to each well and incubated for additional 2 h at 37°C. The optical density was measured at 450 nm with a microplate reader (Bio-Rad Model 680; Bio-Rad Laboratories, Inc.). The cells from each group were added to 6 wells and the experiment was performed in triplicate. In the EdU assay, the stable SKOV3 cell lines were plated in 24-well plates at a density of 5x10^4 cells/well and then treated with 100 ng/ml Dox for 48 h at 37°C. The cells were incubated in serum-free Dulbecco’s modified Eagle’s medium
(DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 50 mM EdU for 2 h at 37°C, after which the nuclei were stained with 1 μg/ml DAPI (cat. no. D9542, Sigma-Aldrich; Merck KGaA) for 10 min at room temperature in the dark. The cells were imaged using an Olympus IX71 fluorescence microscope with excitation wavelengths of 460 nm (green) and 420 nm (blue). The stained cells were counted in 5 randomly selected fields (x100, magnification), and the mean value was calculated.

**Cell cycle analysis.** The effect of LSD1 on cell cycle phase distribution was determined by flow cytometry. The stable LSD1-knockdown SKOV3 cells (1x10⁶ cells/ml) were fixed in 70% ethanol for 30 min at 4°C and stained with 50 μg/ml propidium iodide (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature in the dark. Subsequently, the cell cycle stages were measured with a flow cytometer (FACScan®, BD Biosciences, Franklin Lakes, NJ, USA) equipped with the CellQuest software version 3.3 (BD Biosciences).
SHAO et al.: UNFAVORABLE ROLE OF LSD1 IN CISPLATIN-BASED REGIMENS

Cell apoptosis assay. Cell apoptosis was analyzed with the fluorescein isothiocyanate (FITC) Annexin V apoptosis detection kit (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Briefly, the stable LSD1 knockdown or overexpression SKOV3 cells (5x10^4 cells/well) were treated with 100 ng/ml Dox for 24 h at 37˚C. After 24 h, the cells were exposed to 5 µg/ml cisplatin (Sigma-Aldrich; Merck KGaA) in the presence of Dox for another 48 h at 37˚C. The cells were incubated in 500 µl 1X Annexin V binding buffer at a concentration of 1x10^6 cells/ml. A total of 100 µl of the solution was transferred to a 5-ml culture tube and then stained with 5 µl each of Annexin V-FITC and propidium iodide for 15 min at room temperature in the dark. Following the addition of 400 µl the Annexin V binding buffer to each tube, the samples were analyzed using a flow cytometer (FACScan®, BD Biosciences) equipped with the CellQuest software version 3.3 (BD Biosciences). All these measurements were repeated three times independently.

Cell migration assay. The migration ability of the stable LSD1 knockdown or overexpression SKOV3 cells was assessed as described previously (18). Briefly, 1.5x10^5 cells in 300 µl of serum-free McCoy’s 5A medium were placed in the upper chamber of a Transwell system (BD Biosciences). Then, 500 µl 10% FBS-containing McCoy’s 5A medium was placed in the lower chamber to act as a chemoattractant. After incubation for 24 h at 37˚C, the cells on the upper surface of the membrane (8-µm pore size) were removed with a wet cotton swab. The cells on the lower surface of the membrane were fixed with 4% formaldehyde for 30 min and stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature. The number of the stained cells were counted under a light microscope (BX43; Olympus Corporation, Tokyo, Japan) in 5 random fields (x100, magnification), and the mean value was calculated. All experiments were performed with 3 replicates.

Statistical analysis. All values were presented as means ± standard error of the mean. Differences in different groups were analyzed by Student’s t-test or one-way analysis of variance followed by Tukey's test using SPSS 11.5 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

LSD1 promotes the proliferation of SKOV3 cells. To investigate the effects of LSD1 on the proliferation of SKOV3 ovarian cancer cells, stable LSD1-knockdown (LSD1-KD) clones and LSD1-overexpressing (LSD1-OE) clones were generated using SKOV3 cells in the present study. Total proteins were extracted from the stable cells treated with increasing doses of Dox for 48 h. This time point was chosen based on previous studies (22). The results of the present study revealed that LSD1 protein expression levels were decreased in the LSD1-KD cells in a dose-dependent manner (Fig. 1A), and the reduced expression of LSD1 protein was observed in the pLKO-LSD1-short hairpin RNA; p21^Cip1, cyclin dependent kinase inhibitor 1. 
the expression levels of LSD1 protein were increased in the LSD1-OE cells (Fig. 1D).

To understand the effect of LSD1 expression on cell proliferation, CCK-8 and EdU assays were performed to measure the proliferative capacity of the LSD1-KD and LSD1-OE cells. The LSD1-KD cells demonstrated significantly reduced proliferative ability compared with the control (Fig. 1E and F), whereas the LSD1-OE cells exhibited a higher proliferation rate as compared with the control (Fig. 1G and H).

To further determine the role of LSD1 in cell proliferation, analysis of the cell cycle was conducted via flow cytometry. Knockdown of LSD1 led to an accumulation of cells in the G1 phase (75.8%) compared with the control (61.3%). In addition, there was an notable decrease in the S-phase cell fraction of LSD1-KD cells compared with the control (9.6 vs. 20.8%, respectively; Fig. 2A). Furthermore, knockdown of LSD1 was associated with the significant downregulation of cyclin D1 and CDK2 and the upregulation of p21Cip1 (Fig. 2B). Based on these data, LSD1 silencing may inhibit cell-cycle progression via the G1 phase.

LSD1 regulation of cisplatin-induced inhibition of cell proliferation. Cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma (23). To examine whether LSD1 serves a role in cisplatin resistance, the proliferation of LSD1-OE and LSD1-KD cells in response to cisplatin was analyzed. Treatment with cisplatin resulted in decreased LSD1 level in a dose-dependent manner (Fig. 3A). Cisplatin treatment also caused a dose-dependent reduction in cell proliferation (Fig. 3B). When the cells were cotreated with Dox to induce LSD1-OE, the suppressive effect of cisplatin was significantly reduced (Fig. 3C). Conversely, Dox-mediated LSD1-KD enhanced the cisplatin-induced proliferation inhibition (Fig. 3D). To further
verify the involvement of LSD1 in cisplatin-mediated proliferation inhibition, the expression of two proliferation-associated genes were analyzed. The present study reported that overexpression of LSD1 reversed the cisplatin-induced downregulation of Survivin and upregulation of p21Cip1 for an additional 48 h, and a cell apoptosis assay was performed using Annexin V-FITC. (B) Expression levels of Bcl2 and Bax proteins were detected in the LSD1-KD cells via western blotting. (C) At 24 h following induction via 100 ng/ml Dox, the LSD1-OE cells were exposed to 5 µg/ml cisplatin for an additional 48 h, and a cell apoptosis assay was performed using Annexin V-FITC. (D) Expression levels of Bcl2 and Bax proteins were detected in the LSD1-OE cells via western blotting. (E) After 24 h of induction via 100 ng/ml Dox, the trypsinized LSD1-KD and (F) LSD1-OE cells were seeded in Transwell inserts and cultured with 5 µg/ml cisplatin in the presence of Dox for another 24 h, and then stained with crystal violet. (G) Following treatment with 100 ng/ml Dox for 24 h, the LSD1-KD and (H) LSD1-OE cells were cotreated with 5 µg/ml cisplatin for additional 24 h, after which the protein expression levels of epithelial-mesenchymal transition markers were detected via western blot analysis. Error bars represented data as the means ± standard error of the mean (n=3). *P<0.05, compared with the group not treated with cisplatin and Dox; #P<0.05, compared with the groups treated with cisplatin alone; &P<0.05, compared with the groups treated with Dox alone. Bcl2, B-cell lymphoma-2; Bax, Bcl2-associated X; FITC, fluorescein isothiocyanate; Snail, snail family transcriptional repressor 1.

Impact of LSD1 on cell apoptosis against cisplatin. As cisplatin-induced DNA damage has been associated with the activation of both intrinsic and extrinsic apoptotic pathways (24,25), whether LSD1 is associated with cisplatin-induced apoptosis was investigated in the present study. In the presence of cisplatin, the total cell apoptosis rates in the LSD1-KD group were significantly higher compared with in the corresponding control group (Fig. 4A). Additionally, the expression of proapoptotic protein Bax was notably higher in the LSD1-KD group and (H) LSD1-OE cells were cotreated with 5 µg/ml cisplatin for additional 24 h, after which the protein expression levels of epithelial-mesenchymal transition markers were detected via western blot analysis. Error bars represented data as the means ± standard error of the mean (n=3). *P<0.05, compared with the group not treated with cisplatin and Dox; #P<0.05, compared with the groups treated with cisplatin alone; &P<0.05, compared with the groups treated with Dox alone. Bcl2, B-cell lymphoma-2; Bax, Bcl2-associated X; FITC, fluorescein isothiocyanate; Snail, snail family transcriptional repressor 1.
Effect of LSD1 on cell migration against cisplatin. We have demonstrated previously that LSD1 promotes ovarian cancer cell migration by regulating epithelial-mesenchymal transition (EMT)-associated genes (22). The potential of LSD1 in cell migration in response to cisplatin was investigated in the present study. Cell migration following exposure to cisplatin was significantly inhibited by LSD1-KD (Fig. 4E). Additionally, the inhibition of cell migration was markedly reversed by LSD1-OE (Fig. 4F). In the presence of cisplatin, SKOV3 cells exhibited an upregulation of the epithelial marker E-cadherin and a downregulation of the mesenchymal markers Snail and Vimentin. When the cells were cotreated with Dox to induce LSD1-KD, the cisplatin effects were markedly enhanced (Fig. 4G), whereas Dox-treated LSD1-OE reversed the effects of cisplatin (Fig. 4H). Collectively, these results suggested that LSD1 inhibition and cisplatin may synergistically suppress the migration of SKOV3 cells.

Discussion

LSD1 has been implicated in various types of cancers and serves an oncogenic role in cancer cell proliferation (26,27). The findings of the present study support that the overexpression of LSD1 promotes cell proliferation and inhibits cell apoptosis of SKOV3 ovarian cancer cells. Additionally, the expression levels of LSD1 may be closely associated with the effects of cisplatin. When LSD1 is upregulated, the inhibitory effects of cisplatin are notably inhibited, whereas a reduction of endogenous LSD1 substantially enhances the cisplatin effects. Furthermore, cisplatin may directly downregulate LSD1 protein expression in a dose-response manner, suggesting that LSD1 is a downstream target of cisplatin. Thus, cisplatin may inhibit cell proliferation by modulating epigenetic factors, such as LSD1.

In addressing the molecular mechanisms of the LSD1 inhibitory effect on cisplatin activity, LSD1 silencing was accompanied by a reduced expression in cyclin D1, CDK2, Survivin, and Bcl-2 proteins as observed in the present study, which are known regulators of cell proliferation and survival (28). Importantly, the present study demonstrated that LSD1 knockdown plus cisplatin increased reduction in the expression of these genes. As LSD1 activates gene transcription via the demethylation of H3K9 (29), LSD1 may modulate these gene expressions via epigenetic changes to mediate its cellular function.

One of the notable findings of the present study is that cisplatin-mediated migration inhibition may be partially eliminated by exogenous expression of LSD1, whereas cisplatin plus LSD1 knockdown causes significantly decreased cell migration. This suggests that LSD1 expression is associated with the migration of ovarian cancer cells and may serve a role in the development of cisplatin resistance. Accumulating evidence demonstrates that EMT serves important roles in ovarian cancer metastasis and chemoresistance (22,30). Among the multiple factors, Snail has been recognized as a central transcription factor that controls the EMT program via repressing E-cadherin expression (31,32). It has also demonstrated that mesenchymal cells, which are characterized by the upregulation of Vimentin, may acquire increased migratory potential during tumor progression (32). The results of the present study revealed that LSD1 knockdown may sensitize SKOV3 cells to cisplatin by downregulating Snail and Vimentin protein expression; LSD1-overexpressing cells exhibit the protein expression profiles similar to LSD1-knockdown cells. In the future, it will be beneficial to measure whether LSD1 knockout in vivo sensitizes ovarian tumors to cisplatin.

In conclusion, the present study revealed the role of LSD1 in directing SKOV3 cell proliferation, as well as resistance to cisplatin. Overexpression of LSD1 may stimulate the expression of proliferation-associated genes, thus contributing to the proliferation of SKOV3 cells; sustained expression of LSD1 may overcome cisplatin-induced cell apoptosis. These data identify LSD1 as a regulator of SKOV3 cell potential and provide a possible therapeutic strategy against ovarian cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant no. 81170573) and Clinical Medicine Science & Technology Project of Jiangsu Province (grant no. BL2013024).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GS, CW and QL made substantial contributions to study conception and design, and data acquisition. XW, WL and YW performed western blotting and cell proliferation assays. XL, JJ and LZ participated in cell cycle analysis. XW and QS analyzed the data and were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was endorsed by the Ethics Committee of Jiangsu University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ and Tsang BK: Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum. Ann N Y Acad Sci 1271: 58-67, 2012.
2. Vaughan S, Coward JI, Bart RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al.: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11: 719-725, 2011.

3. Behbakti K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK and Alpaugh RK: Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignant- a: A Gynecologic Oncology Group study. Gynecol Oncol 123: 19-26, 2011.

4. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra I, et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852-861, 2014.

5. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, et al.: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27: 5601-5606, 2009.

6. Lan F, Nottke AC and Shi Y: Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol 20: 316-325, 2008.

7. Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, Günter T, Buettnert R and Schüle R: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436-439, 2005.

8. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettnert R and Kirfel J: Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31: 512-520, 2010.

9. Wu CY, Hsieh CY, Huang KE, Chang C and Kang HY: Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. Int J Cancer 131: 1423-1434, 2012.

10. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettnert R and Kirfel J: Inhibition of the histone demethylase LSD1 mediates epigenetic modification of LSD1 mRNA in human ovarian cancer cells. Gynecol Oncol 123: 755-761, 2012.

11. Schulte KH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, et al.: Selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem 56: 8543-8560, 2013.

12. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Wostner PM and Casero RA Jr: Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 104: 8023-8028, 2007.

13. Zheng YC, Duan YC, Ma JL, Xu RM, Zi X, Lv WL, Wang MM, Ye XW, Zhu S, Mobley D, et al.: Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem 56: 8543-8560, 2013.

14. Harris WJ, Huang X, Lynch JT, Spencer GI, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, et al.: The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21: 472-487, 2012.

15. Schenk T, Chen WC, Günter S, Howell L, Lin J, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et al.: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18: 605-612, 2012.

16. Chen C, Ge J, Lu Q, Ping G, Yang C and Fang X: Expression of lysine-specific demethylase 1 in human epithelial ovarian cancer. J Ovarian Res 8: 28, 2015.